Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y., May 18, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Goldman Sachs 39thAnnual Global Healthcare Conference at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) on Tuesday, June 12, 2018. The session may be accessed from the “Investors

Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO

May 16, 2018 TARRYTOWN, N.Y. and BRIDGEWATER, N.J., May 16, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the first positive Phase 1 clinical data assessing cemiplimab as a potential treatment for advanced non-small cell lung cancer (NSCLC) will be shared at

Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis

TARRYTOWN, N.Y. and PARIS, May 16, 2018 /PRNewswire/ — U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating DUPIXENT® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17)

Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients

TARRYTOWN, N.Y. and BRIDGEWATER, N.J. and ST. LOUIS, May 1, 2018 /PRNewswire/ — Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation Express Scripts to pass on savings to eligible patients from the participating commercial health plans Express Scripts

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

TARRYTOWN, N.Y. and PARIS, April 30, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma

EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

TARRYTOWN, N.Y. and PARIS, April 3, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency(EMA) has accepted for review the Marketing Authorization Application (MAA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients

EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma

TARRYTOWN, N.Y. and PARIS, April 3, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.  (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency(EMA) has accepted for review an application for DUPIXENT® (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older)